Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.04 EUR | -2.59% | +3.20% | +90.32% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.33M 55.79M | Sales 2025 * | 58.9M 64.02M | Capitalization | 75.3M 81.84M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.09M | Net income 2025 * | 3M 3.26M | EV / Sales 2024 * | 1.26 x |
Net cash position 2024 * | 10.53M 11.45M | Net cash position 2025 * | 10.63M 11.56M | EV / Sales 2025 * | 1.1 x |
P/E ratio 2024 * |
57.7
x | P/E ratio 2025 * |
20.4
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | -2.59% | ||
1 week | +3.20% | ||
Current month | +9.44% | ||
1 month | +9.71% | ||
3 months | +36.97% | ||
6 months | +156.82% | ||
Current year | +90.32% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 9.04 | -2.59% | 15,110 |
24-05-16 | 9.28 | +3.11% | 15,527 |
24-05-15 | 9 | +2.27% | 3,742 |
24-05-14 | 8.8 | +2.33% | 1,355 |
24-05-13 | 8.6 | -1.83% | 20,933 |
Delayed Quote Xetra, May 17, 2024 at 11:36 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+90.32% | 81.87M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- APPH Stock